Senseonics Announces Presentation of PROMISE Data at the American Diabetes Association 81st Scientific Sessions
June 28 2021 - 8:00AM
Business Wire
Senseonics Holdings, Inc. (NYSE American: SENS), a medical
technology company focused on the development and commercialization
of the first and only long-term, implantable continuous glucose
monitoring (CGM) system for people with diabetes, today announced
further presentation of PROMISE Study data evaluating the next
generation Eversense CGM System at the American Diabetes
Association Virtual 81st Annual Scientific Sessions.
The data evaluating the safety and accuracy of the next
generation Eversense system was presented by Satish Garg, MD,
Professor of Medicine at the Barbara Davis Center of the University
of Colorado, Denver, and the PROMISE study group Principal
Investigator (PI). The Company presented previously released
information demonstrating performance matching that of the current
90-day sensor available in the United States, with reduced
calibration, down to one per day, with duration extended to 180
days. Accuracy measurements discussed in the oral presentation
include a mean absolute relative difference (MARD) of 9.1% for the
primary sensor and confirmed hypoglycemia alert detection rates at
60 mg/dL of 87% and at 70 mg/dL of 93%. For the subset of 43
modified sensors (referred to as the SBA sensor), the MARD was 8.5%
and the confirmed hypo alert detection rates at 60 mg/dL and 70
mg/dL were 90% and 94%, respectively.
The Eversense CGM System consists of a fluorescence-based
sensor, a smart transmitter worn over the sensor to facilitate data
communication, and a mobile app for displaying glucose values,
trends and alerts. In addition to featuring the first long-term and
first implantable CGM sensor, the system is also first to feature a
smart transmitter that provides wearers with discreet on-body
vibratory alerts for high and low glucose and can be removed,
recharged and re-attached to the skin without discarding the
sensor.
More information on the Eversense system is available at
www.eversensediabetes.com and physicians, nurse practitioners or
physician assistants interested in learning more about the
Eversense CGM System for their patients can contact 844-SENSE4U
(844-736-7348).
About Eversense
The Eversense® Continuous Glucose Monitoring (CGM) System is
indicated for continually measuring glucose levels in persons age
18 and older with diabetes for up to 90 days. The system is
indicated for use to replace fingerstick blood glucose (BG)
measurements for diabetes treatment decisions in the US.
Fingerstick BG measurements are still required for calibration
twice per day, and when symptoms do not match CGM information or
when taking medications of the tetracycline class. The sensor
insertion and removal procedures are performed by a health care
provider. The Eversense CGM System is a prescription device;
patients should talk to their health care provider to learn more.
For important safety information, see
https://eversensediabetes.com/safety-info/.
About Senseonics
Senseonics Holdings, Inc. is a medical technology company
focused on the design, development and commercialization of
transformational glucose monitoring products designed to help
people with diabetes confidently live their lives with ease.
Senseonics' CGM systems, Eversense® and Eversense® XL, include a
small sensor inserted completely under the skin that communicates
with a smart transmitter worn over the sensor. The glucose data are
automatically sent every 5 minutes to a mobile app on the user's
smartphone.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210628005140/en/
Senseonics Investor Contact Lynn Lewis or Philip Taylor
Investor Relations 415-937-5406 investors@senseonics.com
Senseonics Media Contact: Mirasol Panlilio
301-556-1631
Senseonics (AMEX:SENS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Senseonics (AMEX:SENS)
Historical Stock Chart
From Jul 2023 to Jul 2024